亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Comparing the outcome of doublet therapy (gemcitabine and cisplatin) with triplet therapy (gemcitabine, cisplatin and nab paclitaxel) in locally advanced or metastatic gall bladder carcinoma patients: An open-label randomized control trial.

吉西他滨 医学 养生 肿瘤科 内科学 顺铂 膀胱癌 随机对照试验 化疗 癌症
作者
C. Khatri,Priya Das,Jayanta Patowary
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
卷期号:40 (4_suppl): TPS497-TPS497
标识
DOI:10.1200/jco.2022.40.4_suppl.tps497
摘要

TPS497 Background: There are various studies evaluating the role of dual agent chemotherapy like gemcitabine and cisplatin in locally advanced or metastatic gall bladder cancer (1). This has been the standard of treatment up till now. Also there has been a single arm phase II trial of gemcitabine, cisplatin and nab-paclitaxel (triplet therapy) by Shroff et al (2) reporting an impressive data with RR (response rate) of 45 %, median PFS (progression free survival) of 11.8 months (5% CI; 6.0-15.6) and median OS (overall survival) was 19.2 months. This data was promising when compared to historical data of dual agents like gemcitabine and cisplatin. So it would be informative to conduct an RCT comparing doublet chemotherapy in locally advanced or metastatic GBC with triplet regimen chemotherapy. Methods: It is an open label randomized control study conducted in Indraprastha Apollo hospital New Delhi, India in newly diagnosed locally advanced or metastatic gall bladder cancer patients proven histologically and on imaging. The sample size calculated using the appropriate formula is, 27 in each arm that is total of 54 patients, but 60 patients will be enrolled in the study keeping in view 10% drop out rate. For simple randomization, we will use online computer generated random number table and then patients will be assigned in two groups, arms A and B. Arm A receiving two drugs gemcitabine 1,000mg/m2 i.v and cisplatin 25mg/m2 i.v on Day 1 and Day 8 of 21-day cycle and arm B receiving three drugs gemcitabine, 1,000 mg/m2, cisplatin, 25 mg/m2, and nab-paclitaxel, 125 mg/m2, on days 1 and 8 of 21-day cycle. Primary end point was response rates based on radiological response as per RECIST or PRECIST. Secondary end points were to determine median progression free survival and median overall survival and to evaluate the toxicities according to NCI-CTC v 4.0.Then response [on basis of RECIST or PRECIST criteria] will be seen after 3 and 6 cycles of chemotherapy are completed and at follow up of every 6 months for 2 years period for assessment of primary and secondary end points of the study. Statistical analysis for correlation between clinical and laboratory features and treatment outcomes will be done using the SPSS software. Till now we have enrolled 1 patient in each arm. CTRI/2021/09/036362. References: Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;362:1273-81. Shroff RT, Javle MM, Xiao L, et al. Gemcitabine,Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial JAMA Oncol 2019. Clinical trial information: CTRI/2021/09/036362.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
3秒前
怂小包完成签到 ,获得积分10
26秒前
26秒前
MARS完成签到 ,获得积分10
30秒前
33秒前
细心飞鸟发布了新的文献求助10
38秒前
45秒前
pupcoco发布了新的文献求助10
50秒前
桐桐应助mirrovo采纳,获得10
53秒前
雨渺清空完成签到 ,获得积分10
54秒前
55秒前
小二郎应助mirrovo采纳,获得10
1分钟前
LIVE完成签到,获得积分10
1分钟前
风度567发布了新的文献求助10
1分钟前
XJT007完成签到 ,获得积分10
1分钟前
1分钟前
claud完成签到 ,获得积分10
1分钟前
1分钟前
mirrovo发布了新的文献求助10
1分钟前
1分钟前
pupcoco完成签到,获得积分10
1分钟前
风度567完成签到,获得积分10
1分钟前
共享精神应助Andy采纳,获得10
1分钟前
1分钟前
DrY发布了新的文献求助30
1分钟前
CDQ完成签到,获得积分10
1分钟前
luyee发布了新的文献求助10
1分钟前
月亮煮粥发布了新的文献求助10
2分钟前
2分钟前
JamesPei应助科研通管家采纳,获得30
2分钟前
夫诸完成签到 ,获得积分10
2分钟前
楼北完成签到,获得积分10
2分钟前
细心飞鸟完成签到,获得积分10
2分钟前
Omni完成签到,获得积分10
2分钟前
mini的yr完成签到 ,获得积分10
2分钟前
xuzj完成签到,获得积分10
2分钟前
3分钟前
受伤翠容发布了新的文献求助10
3分钟前
3分钟前
受伤翠容完成签到,获得积分20
3分钟前
高分求助中
Un calendrier babylonien des travaux, des signes et des mois: Séries iqqur îpuš 1036
Sustainable Land Management: Strategies to Cope with the Marginalisation of Agriculture 1000
Corrosion and Oxygen Control 600
Heterocyclic Stilbene and Bibenzyl Derivatives in Liverworts: Distribution, Structures, Total Synthesis and Biological Activity 500
重庆市新能源汽车产业大数据招商指南(两链两图两池两库两平台两清单两报告) 400
Division and square root. Digit-recurrence algorithms and implementations 400
行動データの計算論モデリング 強化学習モデルを例として 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2545278
求助须知:如何正确求助?哪些是违规求助? 2175612
关于积分的说明 5600084
捐赠科研通 1896314
什么是DOI,文献DOI怎么找? 946176
版权声明 565334
科研通“疑难数据库(出版商)”最低求助积分说明 503541